| Detail | Information |
|---|---|
| Case Name | SUN PHARMACEUTICAL SDN BHD v. WONG FONG LENG & ORS [2026] 2 MLRH 633 HC |
| Court | High Court Malaya, Kuala Lumpur |
| Judge | Yusrin Faidz Yusoff JC |
| Date of Decision | 1 December 2025 |
| Plaintiff | Sun Pharmaceutical Sdn Bhd (“Sun Pharma”) |
| Defendants | Wong Fong Leng (“D1”), Mazuriah binti Abu Darin (“D2”), and Gan Jia Swee (“D3”) |
| Core Issue | Whether the director (D1) and senior officers (D2 and D3) breached their fiduciary duties and duties of fidelity, leading to the collapse of the company. |
The Court ultimately allowed the Plaintiff’s claim, finding that the business of Sun Pharma had been systematically dismantled by the Defendants.
Judge’s Reasoning and Findings
1. On the Liability of the First Defendant (D1): the Court held that (D1), the director and controlling mind of Sun Pharma was liable based on the direct breach of her statutory and fiduciary duties:
- Highest Duty of Loyalty: D1 owed the highest duty of loyalty and good faith under ss 213 and 218 of the Companies Act 2016. This duty extends beyond prohibiting dishonest gain and includes protecting company assets, avoiding conflicts of interest, and refraining from diverting business opportunities.
- Orchestration of Scheme: The documentary record and evidence showed D1 orchestrated a scheme to dismantle the business. The distributorships were transferred to Sino Health and later Pharma Nord at a time when Sun Pharma was financially stable, which could not be rationally justified.
- Use of Forged Documents and Misrepresentation: The Court was satisfied that D1 orchestrated licence transfers by presenting documents that misrepresented Dr Lim Boon Ping’s (the co-shareholder) approval, allowing her to circumvent governance safeguards. The fabrication of a co-shareholder’s signature was held to be a “grave act of dishonesty” and evidence of her fraudulent intent to advance interests adverse to Sun Pharma.
- Active Influence on Principals: The testimony of the foreign principals (DW1 and DW2) reinforced the conclusion, as they confirmed D1 influenced their decisions to transfer distributorships by portraying risks that were not based on actual operational deficiencies, thus engineering the circumstances that led to the company’s collapse.
2. On the Liability of the Second and Third Defendants (D2 and D3): The Court established that D2 and D3, though starting as employees, held a duty of fidelity and fiduciary obligations due to their senior roles as Regulatory Affairs Manager and Finance Manager, and their subsequent elevation to directors and shareholders of the competing entity, Sino Health.
- Breach of Fidelity: Their conduct was inconsistent with the standard of fidelity expected of senior officers entrusted with confidential data and business continuity functions. Their transition to owners and directors of the new entity was not “incidental, administrative, or neutral,” but directly adverse to Sun Pharma’s interests.
- “Following Instructions” is Not a Defence: The judge rejected the argument that they were absolved because they were merely following D1’s instructions. The duty of fidelity requires a senior employee to refrain from participating in acts harmful to the employer, even if instructed by a superior.
- Rejection of Statutory Relief (s 581): The Court denied them relief under s 581 of the Companies Act 2016, which permits relief if an officer acted honestly and reasonably. The judge reasoned that their involvement in Sino Health—a company receiving Sun Pharma’s assets—without ensuring transparency or obtaining authorisation from Sun Pharma’s shareholders, were serious omissions. Therefore, the Court could not find that they had acted honestly and reasonably.
3. On Causation and Loss: The judge found the losses were a direct result of the Defendants’ breaches, concluding that the business transfer was a “carefully coordinated process carried out with impunity”.
- Causation Established: Causation was established because the wrongful conduct (D1’s failure to protect corporate opportunities and facilitation of the transfer) materially contributed to the loss.
- Damages Accepted: The Court accepted the Plaintiff’s economic and financial narrative, noting the Defendants did not present any competing valuation or expert evidence to challenge the loss computations.
4. Reliefs Granted: The Court found that declaratory, injunctive, compensatory, and exemplary reliefs were appropriate, given the nature and seriousness of the breaches.
- Compensatory Damages (Principle of Restitution): The overriding principle for damages was restitution—to place the Plaintiff in the position it would have been in had the breaches not occurred.
- Loss of Profits (2018-2021): RM33,211,686.00.
- Assets Transferred to Pharma Nord at Undervalue (2021): RM8,972,884.00 (fixed assets and inventory transferred for only RM30,000.00).
- Loss of Future Profits (2022-2026): RM28,802,265.00.
- Loss of Goodwill: RM500,000.00.
- Assets Wrongfully Extracted by D1 (2018-2021): RM1,900,521.00 (cash, antiques, artwork, vehicles).
- Exemplary Damages (Punitive): These were awarded because the breaches were “cynical, calculated and carried out over a period of four years”. D1 was found to have forged documents and disregarded court orders in an effort to strip the company of its business.
- Against D1: RM1,000,000.00.
- Against D2 and D3: RM300,000.00 each.
Disclaimer: This post is for informational purposes only and does not constitute legal advice. Please consult a qualified Advocate & Solicitor for your specific legal needs.
Disclaimer: This case could be subject to further appeal.
